Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorambucil + prednisolone
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chlorambucil + prednisolone is a combination therapy containing the alkylating agent chlorambucil and the corticosteroid prednisolone. Chlorambucil is an immunosuppressant and antineoplastic drug that forms covalent bonds with nucleic acids, disrupting DNA strands and suppressing antibody production. It is most effective during the resting phase of the cell cycle and is cell cycle non-specific. Prednisolone is a steroid hormone that works synergistically with chlorambucil. The combination is more efficacious than single drugs because different drugs kill cancer cells in different ways.
- Other names
- chlorambucil-prednisonechlorambucil-prednisolone
02
Targets
DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on chlorambucil + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorambucil + prednisolone.